title: [In vitro transdermal delivery of the active fraction of xiangfusiwu decoction based on principal component analysis].
abstract: The objective of the present study was to establish a method based on principal component analysis (PCA) for the study of transdermal delivery of multiple components in Chinese medicine, and to choose the best penetration enhancers for the active fraction of Xiangfusiwu decoction (BW) with this method. Improved Franz diffusion cells with isolated rat abdomen skins were carried out to experiment on the transdermal delivery of six active components, including ferulic acid, paeoniflorin, albiflorin, protopine, tetrahydropalmatine and tetrahydrocolumbamine. The concentrations of these components were determined by LC-MS/MS, then the total factor scores of the concentrations at different times were calculated using PCA and were employed instead of the concentrations to compute the cumulative amounts and steady fluxes, the latter of which were considered as the indexes for optimizing penetration enhancers. The results showed that compared to the control group, the steady fluxes of the other groups increased significantly and furthermore, 4% azone with 1% propylene glycol manifested the best effect. The six components could penetrate through skin well under the action of penetration enhancers. The method established in this study has been proved to be suitable for the study of transdermal delivery of multiple components, and it provided a scientific basis for preparation research of Xiangfusiwu decoction and moreover, it could be a reference for Chinese medicine research.
authors.affiliation: Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210046, China.
authors.forename: Zhen-Hao
authors.initials: ZH
authors.lastname: Li
authors.forename: Pei
authors.initials: P
authors.lastname: Liu
authors.forename: Da-Wei
authors.initials: DW
authors.lastname: Qian
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Er-Xin
authors.initials: EX
authors.lastname: Shang
authors.forename: Jin-Ao
authors.initials: JA
authors.lastname: Duan
mesh_terms: D000279:Administration, Cutaneous; D000475:Alkenes / Q000494:pharmacology; D000818:Animals; D001381:Azepines / Q000494:pharmacology; D053119:Benzophenanthridines / Q000302:isolation & purification / Q000493:pharmacokinetics; D001600:Berberine Alkaloids / Q000302:isolation & purification / Q000493:pharmacokinetics; D001952:Bridged-Ring Compounds / Q000302:isolation & purification / Q000493:pharmacokinetics; D003373:Coumaric Acids / Q000302:isolation & purification / Q000493:pharmacokinetics; D004338:Drug Combinations; D004357:Drug Synergism; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000737:chemistry* / Q000302:isolation & purification / Q000493:pharmacokinetics*; D005960:Glucosides / Q000302:isolation & purification / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D008297:Male; D039821:Monoterpenes / Q000302:isolation & purification / Q000493:pharmacokinetics; D010539:Permeability; D010946:Plants, Medicinal / Q000737:chemistry; D025341:Principal Component Analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012869:Skin Absorption / Q000187:drug effects; D006027:Glycosides
chemical_list: D000475:Alkenes; D001381:Azepines; D053119:Benzophenanthridines; D001600:Berberine Alkaloids; D001952:Bridged-Ring Compounds; D003373:Coumaric Acids; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D005960:Glucosides; D039821:Monoterpenes; C035229:laurocapram; C015423:peoniflorin; D006027:Glycosides; C014959:albiflorin; C014215:tetrahydropalmatine; C013658:propylene; C004999:ferulic acid; C092892:tetrahydrocolumbamine; C009093:protopine